Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

FLUMIST TRIVALENT INFLUENZA INTRANASAL VACCINE [SIN17298P]

Active ingredients: INFLUENZA VIRUS (NH) A/CROATIA/10136RV/2023 (H3N2)-LIKE VIRUS (A/PERTH/722/2024) | INFLUENZA VIRUS (NH) A/VICTORIA/4897/2022 (H1N1) PDM09 - LIKE VIRUS (A/NORWAY/31694/2022) | INFLUENZA VIRUS (NH) B/AUSTRIA/1359417/2021 (B/VICTORIA LINEAGE) - LIKE VIRUS (B/AUSTRIA/1359417/2021)

View product's general information
Last updated 28 July 2026

Product Info

FLUMIST TRIVALENT INFLUENZA INTRANASAL VACCINE

[SIN17298P]

Product information

Active Ingredient and Strength

INFLUENZA VIRUS (NH) A/CROATIA/10136RV/2023 (H3N2)-LIKE VIRUS (A/PERTH/722/2024) - 7 ± 0.5 LOG10 FFU/DOSE
INFLUENZA VIRUS (NH) A/VICTORIA/4897/2022 (H1N1) PDM09 - LIKE VIRUS (A/NORWAY/31694/2022) - 7 ± 0.5 LOG10 FFU/DOSE
INFLUENZA VIRUS (NH) B/AUSTRIA/1359417/2021 (B/VICTORIA LINEAGE) - LIKE VIRUS (B/AUSTRIA/1359417/2021) - 7 ± 0.5 LOG10 FFU/DOSE

Dosage Form

SPRAY

Manufacturer and Country

ASTRAZENECA PHARMACEUTICALS LP - UNITED STATES

Registration Number

SIN17298P

Licence Holder

ASTRAZENECA SINGAPORE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

J07BB03

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

1 INDICATIONS AND USAGE

FluMist® Trivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine [see Description (11) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].

FluMist Trivalent is approved for use in persons 2 through 49 years of age [see Clinical Studies (14) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].

Dosing

2 DOSAGE AND ADMINISTRATION

For intranasal use.

2.1 Dosing Information
Administer FluMist Trivalent according to the following schedule:

FluMist Dosage Table 1



2.2 Administration Instructions
Each sprayer contains a single dose (0.2 mL) of FluMist Trivalent; administer approximately one half of the contents of the single-dose intranasal sprayer into each nostril (each sprayer contains 0.2 mL of vaccine). Refer to Figure 1 for step-by-step administration instructions. Following administration, dispose of the sprayer according to the standard procedures for medical waste (e.g., sharps container or biohazard container).

FluMist Dosage Figure 1



Contraindications

4 CONTRAINDICATIONS

4.1 Severe Allergic Reactions
Do not administer FluMist Trivalent to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see Description (11) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information] including egg protein, or after a previous dose of any influenza vaccine.

4.2 Concomitant Aspirin Therapy and Reye’s Syndrome in Children and Adolescents
Do not administer FluMist Trivalent to children and adolescents through 17 years of age who are receiving aspirin therapy or aspirin-containing therapy because of the association of Reye’s syndrome with aspirin and wild-type influenza infection [see Drug Interactions (7.1) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].